Trajectories of cognitive performance over five years in a prospective cohort of patients with breast cancer (NEON-BC).
Breast neoplasms
Cognitive trajectory
Longitudinal studies
Neurocognitive disorders
Journal
Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
21
12
2020
revised:
08
04
2021
accepted:
13
05
2021
pubmed:
24
5
2021
medline:
16
10
2021
entrez:
23
5
2021
Statut:
ppublish
Résumé
To identify trajectories of cognitive performance up to five years since diagnosis and their predictors, in a cohort of patients with breast cancer (BCa). A total of 464 women with BCa admitted to the Portuguese Institute of Oncology, Porto, during 2012, were evaluated with the Montreal Cognitive Assessment (MoCA) before any treatment, and after one, three and five years. Probable cognitive impairment (PCI) at baseline was defined based on normative age- and education-specific reference values. Mclust was used to define MoCA trajectories. Receiver Operating Characteristic curves were used to assess the predictive accuracy for cognitive trajectories. Two trajectories were identified, one with higher scores and increasing overtime, and the other, including 25.9% of the participants, showing a continuous decline. To further characterize each trajectory, participants were also classified as scoring above or below the median baseline MoCA scores. This resulted in four groups: 1) highest baseline scores, stable overtime (0.0% with PCI); 2) lowest baseline scores (29.5% with PCI); 3) mid-range scores at baseline, increasing overtime (10.5% with PCI); 4) mid-range scores at baseline, decreasing overtime (0.0% with PCI). Adding the change in MoCA during the first year to baseline variables significantly increased the accuracy to predict the downward trajectory (area under the curve [AUC] = 0.732 vs. AUC = 0.841, P < 0.001). Four groups of patients with BCa with different cognitive performance trends were identified. The assessment of cognitive performance before treatments and after one year allows for the identification of patients more likely to have cognitive decline in the long term.
Identifiants
pubmed: 34023557
pii: S0960-9776(21)00378-7
doi: 10.1016/j.breast.2021.05.006
pmc: PMC8165446
pii:
doi:
Substances chimiques
Neon
4VB4Y46AHD
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
130-137Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None declared.